Literature DB >> 20023682

Usefulness of RAS inhibition depends on baseline albuminuria.

Sadayoshi Ito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20023682     DOI： 10.1038/nrneph.2009.203

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.

Authors:  Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Journal:  Hypertension       Date:  2005-01-17       Impact factor: 10.190

2.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

3.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

7.  Effect of telmisartan on renal outcomes: a randomized trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Leanne Dyal; Matthew J McQueen; Helmut Schumacher; Janice Pogue; Xingyu Wang; Jeffrey L Probstfield; Alvaro Avezum; Ernesto Cardona-Munoz; Gilles R Dagenais; Rafael Diaz; George Fodor; Jean M Maillon; Lars Rydén; Cheuk M Yu; Koon K Teo; Salim Yusuf
Journal:  Ann Intern Med       Date:  2009-05-18       Impact factor: 25.391

Review 8.  Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk.

Authors:  Sadayoshi Ito; Tasuku Nagasawa; Michiaki Abe; Takefumi Mori
Journal:  Hypertens Res       Date:  2009-01-16       Impact factor: 3.872

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690
  10 in total
  5 in total

1.  Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.

Authors:  Masaru Matsui; Shiro Uemura; Yukiji Takeda; Ken-Ichi Samejima; Takaki Matsumoto; Ayako Hasegawa; Hideo Tsushima; Ei Hoshino; Tomoya Ueda; Katsuhiko Morimoto; Keisuke Okamoto; Sadanori Okada; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Naoki Maruyama; Yasuhiro Akai; Masayuki Iwano; Hideo Shiiki; Yoshihiko Saito
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 2.  Cardiorenal connection in chronic kidney disease.

Authors:  Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

3.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

4.  Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome.

Authors:  Kanako Bokuda; Atsuhiro Ichihara; Mariyo Sakoda; Asako Mito; Kenichiro Kinouchi; Hiroshi Itoh
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

5.  Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.

Authors:  Masato Ohsawa; Kouichi Tamura; Tomohiko Kanaoka; Hiromichi Wakui; Akinobu Maeda; Toru Dejima; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Yuko Tsurumi-Ikeya; Yoshiyuki Toya; Tetsuya Fujikawa; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.